Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091927 | 0.90 | AURKA (0.57) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6092376 | 0.89 | AURKA (0.53) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6027680 | 0.89 | AURKA (0.56) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6027357 | 0.89 | AURKA (0.58) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6091198 | 0.89 | AURKA (0.56) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6028150 | 0.89 | AURKA (0.52) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6091058 | 0.89 | AURKA (0.55) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6027702 | 0.88 | AURKA (0.57) | AURKAAURKBKITPDGFRACSF1R | |
| SCHEMBL6027758 | 0.88 | EGFR (0.56) | AURKAAURKBKITPDGFRACSF1R | |
| Hydrochloric Acid SCHEMBL5039682 | 0.88 | AURKA (0.53) | AURKAAURKBKITPDGFRACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | claimed |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| EP-1644361-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004113324-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885KIT 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.